GC Biopharma Corp. (KRX:006280)

Market Cap	1.54T
Revenue (ttm)	1.71T
Net Income (ttm)	28.73B
Shares Out	11.41M
EPS (ttm)	2,517.06
PE Ratio	53.48
Forward PE	23.34
Dividend	1,500.00 (1.11%)
Ex-Dividend Date	Dec 27, 2024

Volume	59,368
Average Volume	60,929
Open	137,900
Previous Close	135,400
Day's Range	134,600 - 139,900
52-Week Range	111,800 - 181,800
Beta	1.14
RSI	43.21
Earnings Date	Aug 14, 2025

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,009
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 006280

Financial Performance

In 2024, GC Biopharma's revenue was 1.68 trillion, an increase of 3.27% compared to the previous year's 1.63 trillion. Losses were -26.28 billion, -1.32% less than in 2023.